Adimab team accuses prominent MIT investigator Ram Sasisekharan of ripping off antibodies and presenting them as his own
Dartmouth professor and longtime Adimab chief Tillman Gerngross is calling out noted MIT investigator Ram Sasisekharan for ripping off the work of others in the antibody field and passing it off as his own “extraordinary” design done in silico. And one of those antibodies was at the center of a recent $430 million buyout.
“We assembled the facts, we checked the facts with the leading antibody experts outside of Adimab and they all agreed with us,” Gerngross tells me. “If you look at the facts it looks like serious misconduct.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.